FDA Investigator Xiomara Copeland
Xiomara Copeland has conducted inspections on 16 sites in 6 countries as of 15 Jul 2019. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
16
Last Inspection Date:
15 Jul 2019
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
Spain,
Austria,
India,
United States of America,
United Kingdom of Great Britain and Northern Ireland,
Portugal
FDA Investigators that have inspected at least one site in common with Xiomara Copeland:
Adam R Cooke,
Ademola O Daramola,
Alexander M Kay,
Amy H Ruble,
Ana L Kewes,
Anita Narula, PhD,
Ashar P Parikh,
Astrida B Mattson,
Atul J Agrawal,
Babatunde D Babalola,
Barbara Janine Breithaupt,
Barbara M Frazier,
Barbara T Carmichael,
Bijoy Panicker,
Bonita S Chester,
Bradley Dworak, PhD,
Brandy D Brown,
Brentley S Collins,
Brett D Weed,
Brett Weed,
Calvin Foulks,
Carla J Lundi,
Carolyn E Barney,
Caryn M Mcnab,
Cassandra L Abellard,
CDR Thomas R Berry, PPh,
Chauncey A Stephens,
Christian D Lynch (CDL),
Christine A Harman, PhD,
Christopher D Leach,
Chryste D Best,
Claudette D Brooks,
Concepcion Cruz, Jr,
Connie P Rezendes,
Cordelia J Brammer,
Cynthia J Lee, MS,
Daphne Santiago, PhD,
David J Leray,
David T Glover,
Dawn E Barkans,
Dawn M Braswell,
Dawn P Hall,
Dellarese L Herbert,
Demario L Walls,
Denise M Digiulio,
Derek C Price,
Devaughn Edwards,
Dolores E Price,
Don H Bark, PhD,
Dr. Barbara D Paul, PhD,
Dr. Jason R Caballero,
Edmund F Mrak, Jr,
Edward Lukeman,
Edwin Melendez,
Eileen A Liu,
Felix Maldonado,
Fulton A Varner,
Gerard Pde Leon,
Gideon N Esuzor,
Gloria J Baca, MS,
Gwyn G Dickinson,
Heika R Bounds,
Heika R Tait,
Helen R Bester,
Ibad U Khan,
Inga M Warr,
Ingrid A Zambrana,
Jackie M Douglas,
Jacqueline Mdiaz Albertini,
Janet B Gray,
Jason F Chancey,
Jawaid Hamid,
Jennifer L Bridgewater,
Jigar R Patel,
Joey V Quitania,
Jose A Lopez,
Jose Acruz Gonzalez,
Jose M Cayuela,
Joseph F Owens,
Justin A Boyd,
Kantrell D Smith,
Karen A Coleman,
Kari M Johansen,
Katherine Szestypalow,
Kathleen D Culver,
Kathryn A Krentz,
Katrina B Mosley Sloan,
Kenneth O Gee, PhD,
Keri U Walker,
Kevin A Gonzalez,
Kevin D Kallander,
Khalid M Khan,
Kimberly Cdelk Brooks,
Kip J Hanks,
Kristin M Abaonza,
Lakisha N Morton,
Latonya T Jiggetts,
Laurel A Beer,
Lauryl A Smith,
LCDR Debra Emerson,
Leah M Andrews,
Lesley K Satterwhite,
Leslie W Gilbert,
Linda F Murphy,
Linda M Athey,
Linda Thai,
Lisa K Capron,
LT Tamara J Henderson,
Lynda L Perry, PhD,
Maria Pkelly Doggett, MBA,
Marian A Kainer,
Marie B Buen Bigornia,
Marie F Morin,
Marijo B Kambere, PhD,
Marisa E Stock,
Mariza M Jafary,
Mark W Babbitt,
Mary A Millner,
Matthew B Casale,
Maxine H Wong,
Melanie M Walker,
Melissa J Garcia,
Miaja Umaedi,
Michael A Charles,
Michael E Maselli,
Mihaly S Ligmond,
Mikel T Wright,
Mra B Kamberem,
Mra Davism,
Muralidhara B Gavini, PhD,
Myoshi M Francis,
N'jere English,
Nadeem I Chaudhry,
Niketa Patel,
Noreen Muñiz,
Omotunde O Osunsanmi,
Paraluman S Leonin,
Parul M Patel,
Patricia F Hudson,
Paul A Bonneau,
Paula A Trost,
Penny H Mccarver,
Perry H Gambrell,
Phuong L Tran,
Prabhu P Raju,
Rachael A Moliver,
Randy L Self,
Rebecca Rodriguez,
Rhonda Alexander,
Robert C Coleman,
Robert D Tollefsen,
Robert M Barbosa,
Ronnie E Jackson,
Rose Xu,
S Lori Brown, PhD MPH,
Safronia Jenkins,
Samantha J Bradley,
Sandra I Gaul,
Sangeeta M Khurana, PhD,
Sangeeta M Rataul,
Satheesh Thomas,
Saundrea A Munroe,
Sayeeda Hdabe,
Seneca D Toms,
Simone M Edmonson,
Sonya M Edmonds,
Stephanie E Hubbard,
Steven C Madzo,
Susan F Laska, MS,
Susan P Bruederle,
Tamara M Felton,
Tammara A Stephens,
Terri L Dodds,
Thomas J Arista,
Tina S Roecklein,
Tracy K Li,
Tracy R Ball,
Trang N Cox,
Uttaniti Limchumroon (Tom),
Vanessa E Coulter,
Vincent M Williams,
Viviana Matta,
William J Leonard,
Zachary A Bogorad
Xiomara Copeland's Documents
Publish Date | Document Type | Title |
---|---|---|
July, 2019 | EIR | Jubilant HollisterStier LLC - EIR, 2019-07-26 |
August, 2015 | FDA 483 | Amneal Pharmaceuticals Private Limited - Form 483, 2015-08-25 |
June, 2014 | EIR | Hospira, Inc. - EIR, 2014-06-13 |
April, 2016 | FDA 483 | HIKMA FARMACEUTICA (PORTUGAL), S.A - Form 483, 2016-04-12 |
September, 2015 | FDA 483 | Orchid Pharma Limited - Form 483, 2015-09-04 |
July, 2019 | FDA 483 | Jubilant HollisterStier LLC - Form 483, 2019-07-26 |
March, 2014 | FDA 483 | S.s.s. Company (international) - Form 483, 2014-03-31 |
April, 2016 | FDA 483 | ROVI Pharma Industrial Services S.A. - Form 483, 2016-04-22 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more